Gemnil 200mg & 1gm injection Vial

Name Gemnil
Description Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolized intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalyzing the reactions that produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP reduces the concentration of deoxynucleosides in general and, in particular, dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).
Active Ingredient Gemcitabine
Indication Gemcitabine in combination therapy is indicated for the following cancer types:
  • Advanced or metastatic bladder cancer
  • Advanced or metastatic adenocarcinoma of the pancreas.
  • Advanced or metastatic non-small cell lung cancer (NSCLC).
  • Advanced or metastatic epithelial ovarian carcinoma
Locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Strengths 200mg & 1gm injection Vial
Business Partner Auromedics
Origin USA